Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
نویسندگان
چکیده
منابع مشابه
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticle...
متن کاملPolymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
Oncolytic viruses (OV) could become the most powerful and selective cancer therapies. However, the limited transport of OV into and throughout tumors following intravenous injection means their clinical administration is often restricted to direct intratumoral dosing. Application of physical stimuli, such as focused ultrasound, offers a means of achieving enhanced mass transport. In particular,...
متن کاملDirecting systemic oncolytic viral delivery to tumors via carrier cells.
The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesenchymal and neural stem cells have been described to possess tumor-homing ability as well as the ...
متن کاملImmunotherapeutic Potential of Oncolytic Vaccinia Virus
The concept of oncolytic viral therapy was based on the hypothesis that engineering tumor-selectivity into the replication potential of viruses would permit direct destruction of tumor cells as a result of viral-mediated lysis, resulting in amplification of the therapy exclusively within the tumor environment. The immune response raised by the virus was not only considered to be necessary for t...
متن کاملSendai Virus-Based Oncolytic Gene Therapy
The first gene therapy that was used on humans was performed for adenosine deaminase (ADA) deficiency in 1990 [1]. In the early days of gene therapy, it was thought to be a break‐ through in the treatment of a number of human diseases including cancer, cardiovascular disease, genetic disease, and so on. However, two severe adverse events in gene therapy served as triggers for the rethinking of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncolytic Virotherapy
سال: 2017
ISSN: 2253-1572
DOI: 10.2147/ov.s145262